Ryzneuta Interactions
There are 178 drugs known to interact with Ryzneuta (efbemalenograstim alfa), along with 1 disease interaction. Of the total drug interactions, 3 are major, and 175 are moderate.
- View all 178 medications that may interact with Ryzneuta
- View Ryzneuta disease interactions (1)
Most frequently checked interactions
View interaction reports for Ryzneuta (efbemalenograstim alfa) and the medicines listed below.
- Actimmune (interferon gamma-1b)
- Adcetris (brentuximab)
- Adcirca (tadalafil)
- Adzynma (apadamtase alfa, recombinant)
- Aimovig (erenumab)
- ambrisentan
- Amondys 45 (casimersen)
- apremilast
- Aubagio (teriflunomide)
- Augtyro (repotrectinib)
- Austedo XR (deutetrabenazine)
- Bafiertam (monomethyl fumarate)
- Benlysta (belimumab)
- Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide)
- Bimzelx (bimekizumab)
- Blincyto (blinatumomab)
- bosentan
- Braftovi (encorafenib)
- Breyanzi (lisocabtagene maraleucel)
- Brilinta (ticagrelor)
- Brineura (cerliponase alfa)
- Briumvi (ublituximab)
- Brukinsa (zanubrutinib)
- Bylvay (odevixibat)
- Cabenuva (cabotegravir / rilpivirine)
- Cablivi (caplacizumab)
- Calquence (acalabrutinib)
- Camzyos (mavacamten)
- Caplyta (lumateperone)
- Caprelsa (vandetanib)
Ryzneuta disease interactions
There is 1 disease interaction with Ryzneuta (efbemalenograstim alfa) which include:
Report options
QR code containing a link to this page
More about Ryzneuta (efbemalenograstim alfa)
- Ryzneuta consumer information
- Compare alternatives
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: colony stimulating factors
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
